Now showing items 1-7 of 7

    • A new method for the high-precision assessment of tumor changes in response to treatment. 

      Tar, PD; Thacker, NA; Babur, M; Watson, Y; Cheung, S; Little, RA; Gieling, RG; Williams, KJ; O'Connor, JPB (2018-08)
      Motivation:Imaging demonstrates that preclinical and human tumors are heterogeneous, i.e. a single tumor can exhibit multiple regions that behave differently during both development and also in response to treatment. The ...
    • Assessing methods for dealing with treatment switching in clinical trials: A follow-up simulation study. 

      Latimer, NR; Abrams, KR; Lambert, PC; Morden, JP; Crowther, MJ (2018-03)
      When patients randomised to the control group of a randomised controlled trial are allowed to switch onto the experimental treatment, intention-to-treat analyses of the treatment effect are confounded because the separation ...
    • Development of a framework to improve the process of recruitment to randomised controlled trials (RCTs): the SEAR (Screened, Eligible, Approached, Randomised) framework. 

      Wilson, C; Rooshenas, L; Paramasivan, S; Elliott, D; Jepson, M; Strong, S; Birtle, A; Beard, DJ; Halliday, A; Hamdy, FC; Lewis, R; Metcalfe, C; Rogers, CA; Stein, RC; Blazeby, JM; Donovan, JL (2018-01-19)
      Background Research has shown that recruitment to trials is a process that stretches from identifying potentially eligible patients, through eligibility assessment, to obtaining informed consent. The length and complexity ...
    • Evaluating a digital tool for supporting breast cancer patients: a randomized controlled trial protocol (ADAPT). 

      Lidington, E; McGrath, SE; Noble, J; Stanway, S; Lucas, A; Mohammed, K; van der Graaf, W; Husson, O (2020-01-15)
      BACKGROUND:There are a growing number of mHealth tools for breast cancer patients but a lack of scientific evidence for their effects. Recent studies have shown a mix of positive and negative impacts on users. Here we will ...
    • gsSKAT: Rapid gene set analysis and multiple testing correction for rare-variant association studies using weighted linear kernels. 

      Larson, NB; McDonnell, S; Cannon Albright, L; Teerlink, C; Stanford, J; Ostrander, EA; Isaacs, WB; Xu, J; Cooney, KA; Lange, E; Schleutker, J; Carpten, JD; Powell, I; Bailey-Wilson, JE; Cussenot, O; Cancel-Tassin, G; Giles, GG; MacInnis, RJ; Maier, C; Whittemore, AS; Hsieh, C-L; Wiklund, F; Catalona, WJ; Foulkes, W; Mandal, D; Eeles, R; Kote-Jarai, Z; Ackerman, MJ; Olson, TM; Klein, CJ; Thibodeau, SN; Schaid, DJ (2017-05)
      Next-generation sequencing technologies have afforded unprecedented characterization of low-frequency and rare genetic variation. Due to low power for single-variant testing, aggregative methods are commonly used to combine ...
    • PSA levels and cancer detection rate by centre in the European Randomized Study of Screening for Prostate Cancer. 

      Otto, SJ; Moss, SM; Määttänen, L; Roobol, M; Zappa, M; Nelen, V; Kwiatkowski, M; Villers, A; Hugosson, J; Sanchez, AB; de Koning, HJ (2010-11)
      Background To describe the variation in PSA level by age group and screening round in the ERSPC centres and the variation in cancer detection rates in relation to the underlying prostate cancer incidence.Methods Individual ...
    • The effect of sample size on polygenic hazard models for prostate cancer. 

      Karunamuni, RA; Huynh-Le, M-P; Fan, CC; Eeles, RA; Easton, DF; Kote-Jarai, Z; Amin Al Olama, A; Benlloch Garcia, S; Muir, K; Gronberg, H; Wiklund, F; Aly, M; Schleutker, J; Sipeky, C; Tammela, TLJ; Nordestgaard, BG; Key, TJ; Travis, RC; Neal, DE; Donovan, JL; Hamdy, FC; Pharoah, P; Pashayan, N; Khaw, K-T; Thibodeau, SN; McDonnell, SK; Schaid, DJ; Maier, C; Vogel, W; Luedeke, M; Herkommer, K; Kibel, AS; Cybulski, C; Wokolorczyk, D; Kluzniak, W; Cannon-Albright, L; Brenner, H; Schöttker, B; Holleczek, B; Park, JY; Sellers, TA; Lin, H-Y; Slavov, C; Kaneva, R; Mitev, V; Batra, J; Clements, JA; Spurdle, A; Australian Prostate Cancer BioResource (APCB); Teixeira, MR; Paulo, P; Maia, S; Pandha, H; Michael, A; Mills, IG; Andreassen, OA; Dale, AM; Seibert, TM; PRACTICAL Consortium
      We determined the effect of sample size on performance of polygenic hazard score (PHS) models in prostate cancer. Age and genotypes were obtained for 40,861 men from the PRACTICAL consortium. The dataset included 201,590 ...